Takeda Pharmaceutical Company Limited (TAK)

$13.33

+0.04

(+0.3%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Performance

  • $13.25
    $13.35
    $13.33
    downward going graph

    0.6%

    Downside

    Day's Volatility :0.75%

    Upside

    0.15%

    downward going graph
  • $12.58
    $15.08
    $13.33
    downward going graph

    5.66%

    Downside

    52 Weeks Volatility :16.61%

    Upside

    11.6%

    downward going graph

Returns

PeriodTakeda Pharmaceutical Company LimitedSector (Health Care)Index (Russel 2000)
3 Months
-10.42%
-6.9%
0.0%
6 Months
2.07%
-1.7%
0.0%
1 Year
-4.79%
10.4%
0.0%
3 Years
-3.48%
8.8%
-24.1%

Highlights

Market Capitalization
42.2B
Book Value
$4365.91
Dividend Share
192.0
Dividend Yield
4.29%
Earnings Per Share (EPS)
0.59
PE Ratio
22.53
PEG Ratio
0.7
Wall Street Target Price
2481.072
Profit Margin
6.38%
Operating Margin TTM
20.54%
Return On Assets TTM
2.78%
Return On Equity TTM
4.15%
Revenue TTM
4.5T
Revenue Per Share TTM
1445.88
Quarterly Revenue Growth YOY
12.7%
Gross Profit TTM
2.4T
EBITDA
1.3T
Diluted Eps TTM
0.59
Quarterly Earnings Growth YOY
0.05
EPS Estimate Current Year
0.33
EPS Estimate Next Year
0.48
EPS Estimate Current Quarter
0.57
EPS Estimate Next Quarter
0.63

Analyst Recommendation

Buy
    52%Buy
    47%Hold
    0
    0%Sell
Based on 23 Wall street analysts offering stock ratings for Takeda Pharmaceutical Company Limited(by analysts ranked 0 to 5 stars)
Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
11
11
11
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 18512.69%

Current $13.33
Target $2,481.07

Company Financials

FY19Y/Y Change
Revenue
18.9B
↑ 18.45%
Net Income
981.7M
↓ 41.61%
Net Profit Margin
5.2%
↓ 5.36%
FY20Y/Y Change
Revenue
30.6B
↑ 56.93%
Net Income
411.6M
↓ 59.46%
Net Profit Margin
1.34%
↓ 3.86%
FY21Y/Y Change
Revenue
29.4B
↓ 2.84%
Net Income
3.5B
↑ 749.9%
Net Profit Margin
11.76%
↑ 10.42%
FY22Y/Y Change
Revenue
30.2B
↑ 11.61%
Net Income
1.9B
↓ 38.81%
Net Profit Margin
6.45%
↓ 5.31%
FY23Y/Y Change
Revenue
30.1B
↑ 12.85%
Net Income
2.4B
↑ 37.8%
Net Profit Margin
7.87%
↑ 1.42%
FY24Y/Y Change
Revenue
28.5B
↑ 5.87%
Net Income
961.7M
↓ 54.56%
Net Profit Margin
3.38%
↓ 4.49%
Q2 FY23Q/Q Change
Revenue
7.4B
↑ 9.09%
Net Income
-339.7M
↓ 254.27%
Net Profit Margin
-4.6%
↓ 7.86%
Q3 FY23Q/Q Change
Revenue
7.1B
↑ 0.0%
Net Income
-324.9M
↑ 0.0%
Net Profit Margin
-4.6%
↑ 0.0%
Q4 FY23Q/Q Change
Revenue
7.7B
↑ 6.53%
Net Income
735.0M
↓ 320.11%
Net Profit Margin
9.51%
↑ 14.11%
Q1 FY24Q/Q Change
Revenue
8.1B
↑ 8.71%
Net Income
635.8M
↓ 9.91%
Net Profit Margin
7.88%
↓ 1.63%
Q2 FY24Q/Q Change
Revenue
7.6B
↑ 0.0%
Net Income
602.7M
↑ 0.0%
Net Profit Margin
7.88%
↑ 0.0%
Q3 FY24Q/Q Change
Revenue
1.2T
↓ 2.65%
Net Income
92.0B
↓ 3.36%
Net Profit Margin
7.83%
↓ 0.05%
FY19Y/Y Change
Total Assets
124.8B
↑ 237.82%
Total Liabilities
78.3B
↑ 316.87%
FY20Y/Y Change
Total Assets
119.3B
↓ 7.58%
Total Liabilities
75.3B
↓ 7.06%
FY21Y/Y Change
Total Assets
118.8B
↑ 0.71%
Total Liabilities
71.2B
↓ 4.43%
FY22Y/Y Change
Total Assets
111.4B
↑ 2.06%
Total Liabilities
63.3B
↓ 3.11%
FY23Y/Y Change
Total Assets
104.4B
↑ 5.92%
Total Liabilities
56.9B
↑ 1.45%
FY24Y/Y Change
Total Assets
100.9B
↑ 8.25%
Total Liabilities
52.3B
↑ 3.05%
Q2 FY23Q/Q Change
Total Assets
105.2B
↑ 6.55%
Total Liabilities
55.2B
↑ 2.6%
Q3 FY23Q/Q Change
Total Assets
100.6B
↑ 0.0%
Total Liabilities
52.8B
↑ 0.0%
Q4 FY23Q/Q Change
Total Assets
98.9B
↓ 4.36%
Total Liabilities
52.0B
↓ 4.11%
Q1 FY24Q/Q Change
Total Assets
108.3B
↑ 14.1%
Total Liabilities
56.3B
↑ 12.67%
Q2 FY24Q/Q Change
Total Assets
102.7B
↑ 0.0%
Total Liabilities
53.3B
↑ 0.0%
Q3 FY24Q/Q Change
Total Assets
14.6T
↓ 10.2%
Total Liabilities
7.7T
↓ 9.22%
FY19Y/Y Change
Operating Cash Flow
3.0B
↓ 13.07%
Investing Cash Flow
-25.5B
↑ 2937.97%
Financing Cash Flow
26.5B
↓ 1003.13%
FY20Y/Y Change
Operating Cash Flow
6.2B
↑ 103.89%
Investing Cash Flow
2.7B
↓ 110.3%
Financing Cash Flow
-9.4B
↓ 134.12%
FY21Y/Y Change
Operating Cash Flow
9.3B
↑ 50.94%
Investing Cash Flow
3.6B
↑ 34.72%
Financing Cash Flow
-10.0B
↑ 8.27%
FY22Y/Y Change
Operating Cash Flow
9.5B
↑ 11.1%
Investing Cash Flow
-1.7B
↓ 150.35%
Financing Cash Flow
-9.0B
↓ 1.66%
FY23Y/Y Change
Operating Cash Flow
7.3B
↓ 13.0%
Investing Cash Flow
-4.5B
↑ 206.42%
Financing Cash Flow
-5.3B
↓ 33.74%
Q2 FY23Q/Q Change
Operating Cash Flow
1.4B
↓ 32.27%
Investing Cash Flow
-1.9B
↓ 56.1%
Financing Cash Flow
-994.8M
↑ 2031.14%
Q3 FY23Q/Q Change
Operating Cash Flow
1.3B
↑ 0.0%
Investing Cash Flow
-2.2B
↑ 22.73%
Financing Cash Flow
-951.5M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Takeda Pharmaceutical Company Limited is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
-5.66%
2.07%
-4.79%
-3.48%
-34.59%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
7.04%
-10.35%
12.63%
45.35%
9.32%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-3.63%
12.35%
14.51%
28.88%
28.88%
Zoetis Inc.
Zoetis Inc.
-6.75%
2.71%
-1.47%
-21.23%
47.49%
Viatris Inc.
Viatris Inc.
13.54%
21.84%
41.41%
0.99%
-18.91%
Catalent, Inc.
Catalent, Inc.
-0.43%
8.53%
50.66%
-53.63%
14.64%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
22.53
22.53
0.7
0.33
0.04
0.03
0.04
4365.91
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
33.33
33.33
0.29
6.54
0.16
0.12
NA
26.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
27.88
27.88
1.69
0.34
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
33.0
33.0
2.46
5.87
0.47
0.15
0.01
11.59
Viatris Inc.
Viatris Inc.
224.4
NA
0.08
2.67
-0.04
0.02
0.04
16.58
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.95
0.2
-0.11
0.0
NA
19.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
Buy
$42.2B
-34.59%
22.53
6.38%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$12.7B
9.32%
33.33
17.21%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$42.9B
28.88%
27.88
10.75%
Zoetis Inc.
Zoetis Inc.
Buy
$79.2B
47.49%
33.0
26.55%
Viatris Inc.
Viatris Inc.
Hold
$15.1B
-18.91%
224.4
-5.87%
Catalent, Inc.
Catalent, Inc.
Hold
$10.7B
14.64%
211.02
-9.34%

Insights on Takeda Pharmaceutical Company Limited

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1207.99B → 1176.03B (in $), with an average decrease of 2.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, 105.72B → 92.04B (in $), with an average decrease of 4.4% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 50.7% return, outperforming this stock by 55.5%

Institutional Holdings

  • Capital Research Global Investors

    0.41%

  • Morgan Stanley - Brokerage Accounts

    0.31%

  • Mondrian Investment Partners Ltd

    0.24%

  • Millennium Management LLC

    0.14%

  • Goldman Sachs Group Inc

    0.12%

  • Renaissance Technologies Corp

    0.10%

Corporate Announcements

  • Takeda Pharmaceutical Company Limited Dividends March,2022

    In the quarter ending March,2022. Takeda Pharmaceutical Company Limited has declared dividend of $0.33

    Read More

Company Information

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue.

Organization
Takeda Pharmaceutical Company Limited
Employees
49281
CEO
Mr. Christophe Weber
Industry
Health Technology

FAQs